ArticlePloS one2025
Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Evaluating the Effectiveness of Commercial Oral Supplements for Hair Growth: A Systematic Review and Meta-Analysis.Journal of cosmetic dermatology · 2026Pooled it
- Pungenin Promotes Hair Growth in Mouse Models of Androgenic Alopecia Through Transcriptional Regulation of the PI3K/AKT/mTOR Axis.Molecules (Basel, Switzerland) · 2026Article
- Taurine-based Active Pharmaceutical Ingredient Ionic Liquids Modulate the Perifollicular Microenvironment for Androgenic Alopecia Treatment.Advanced healthcare materials · 2026Article
- Dyslipidemia, hormonal profiles, and sleep characteristics in men with androgenetic alopecia: an analysis based on data from the EPISONO study.Hormones (Athens, Greece) · 2026Article
- Beyond the Follicle: A Narrative Review on How Systemic Diseases and Drugs Affect Alopecia.Pharmaceutical medicine · 2026Review
- The Genetic Landscape of Androgenetic Alopecia: Current Knowledge and Future Perspectives.Biology · 2026Review
- Targeted transferosomal delivery of cetirizine: A new approach to alopecia management.PloS one · 2026Article
- Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics.PloS one · 2026Article
- Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.Aesthetic plastic surgery · 2025Review
- Novel Strategies for Androgenetic Alopecia Therapy: Integrating Multifunctional Plant Extracts with Nanotechnology for Advanced Cutaneous Drug Delivery.Pharmaceutics · 2025Review
- Real-world pharmacovigilance insights into drug-induced risk of alopecia.Frontiers in pharmacology · 2025Article
- Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us.PloS one · 2025Article
- Stem cell-based approaches for alopecia: A narrative review of current and emerging treatment strategies.Cell transplantationReview
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAndrogenetic alopecia (AGA) is extremely prevalent with a multifactorial etiology. MATERIALS: We conducted a cross-sectional study using the All of US (AoU) dataset Sept 2024 to better understand the epidemiology, social determinants and management of AGA.
resultsMost males were 20-39 years old and females 60-69 years old. Men typically have an earlier onset of AGA than females. Male AGA is generally managed with finasteride; oral minoxidil is prescribed in younger males. Females are prescribed spironolactone and oral minoxidil with finasteride in post-menopausal females. There was very little dutasteride prescribed. Topical minoxidil is available over the counter and was not evaluated. Early in 2011 there were reports of the Post-Finasteride Syndrome (PFS); subsequently, the finasteride prescription rate fell to about 10-20% of the pre-PFS prescription rate. There was increased reporting for AGA in those who drink, have an annual household income ≥$75,000, and those with a higher level of education. There was also higher reporting of female AGA in those with anxiety and depression. Patients with higher income and education may have less pressing medical concerns enabling them to bring their AGA to the physician's attention. Females in whom the AGA affects their anxiety and depression may seek help for the AGA as a way to address their underlying disorder.
conclusionsThis study provides a snapshot of the epidemiology and management of AGA in the USA. AGA is linked to the social determinants of health; addressing the AGA may help better manage the underlying mental and physical state.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.